Why is Hester Bios falling/rising?

As of 17-Jul, Hester Biosciences Ltd is experiencing a price increase, currently at 1,946.45, reflecting a rise of 101.45 or 5.5%. The stock has shown strong performance today, outperforming its sector by 5.08% and reaching an intraday high of Rs 2057.75, which is an increase of 11.53%. Over the past week, the stock has gained 8.72%, while it has also seen a 6.94% increase over the last month. The company has reported positive results for the last four consecutive quarters, with a significant growth in profit after tax of 45.02%. However, it faces challenges such as a high Debt to EBITDA ratio of 3.49 times, indicating a low ability to service debt, and a poor long-term growth outlook with net sales growing at an annual rate of only 11.16% over the past five years.
In the broader market context, while Hester Bios has shown positive short-term returns, it has significantly underperformed the benchmark, the Sensex, which has gained 0.83% over the past month. The stock's year-to-date performance is notably poor, with a decline of 18.65%, contrasting sharply with the Sensex's increase of 5.27%. Despite the recent uptick in price, the stock has generated a return of -31.94% over the past year, indicating ongoing investor concerns. The low domestic mutual fund participation, at 0%, suggests a lack of confidence in the stock's valuation, despite its recent positive earnings growth.